Our top pick for
Surface Oncology, Inc is a biotechnology business based in the US. Surface Oncology shares (SURF) are listed on the NASDAQ and all prices are listed in US Dollars. Surface Oncology employs 49 staff and has a trailing 12-month revenue of around USD$39 million.
Since the stock market crash in March caused by coronavirus, Surface Oncology's share price has had significant positive movement.
Its last market close was USD$7.99, which is 51.81% up on its pre-crash value of USD$3.85 and 478.99% up on the lowest point reached during the March crash when the shares fell as low as USD$1.38.
If you had bought USD$1,000 worth of Surface Oncology shares at the start of February 2020, those shares would have been worth USD$493.72 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,512.62.
|Latest market close||USD$7.99|
|52-week range||USD$1.38 - USD$10.25|
|50-day moving average||USD$8.3943|
|200-day moving average||USD$6.0966|
|Wall St. target price||USD$13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.327|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-13)||-7.20%|
|1 month (2020-10-21)||-10.12%|
|3 months (2020-08-21)||27.23%|
|6 months (2020-05-21)||34.29%|
|1 year (2019-11-21)||278.67%|
|2 years (2018-11-21)||-4.77%|
|3 years (2017-11-20)||N/A|
|5 years (2015-11-20)||N/A|
|Revenue TTM||USD$39 million|
|Gross profit TTM||USD$-36,758,000|
|Return on assets TTM||-9.48%|
|Return on equity TTM||-30.91%|
|Market capitalisation||USD$325 million|
TTM: trailing 12 months
There are currently 1.0 million Surface Oncology shares held short by investors – that's known as Surface Oncology's "short interest". This figure is 56.6% up from 656,489 last month.
There are a few different ways that this level of interest in shorting Surface Oncology shares can be evaluated.
Surface Oncology's "short interest ratio" (SIR) is the quantity of Surface Oncology shares currently shorted divided by the average quantity of Surface Oncology shares traded daily (recently around 1.3 million). Surface Oncology's SIR currently stands at 0.82. In other words for every 100,000 Surface Oncology shares traded daily on the market, roughly 820 shares are currently held short.
However Surface Oncology's short interest can also be evaluated against the total number of Surface Oncology shares, or, against the total number of tradable Surface Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surface Oncology's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Surface Oncology shares in existence, roughly 30 shares are currently held short) or 0.0354% of the tradable shares (for every 100,000 tradable Surface Oncology shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Surface Oncology.
Find out more about how you can short Surface Oncology stock.
We're not expecting Surface Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Surface Oncology's shares have ranged in value from as little as $1.38 up to $10.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surface Oncology's is 2.2715. This would suggest that Surface Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDAÂ (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.